Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Search for FDA Guidance Documents

Search for FDA Guidance Documents

                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents Home
          Regulatory Information
          Search for FDA Guidance Documents
          Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4Search for FDA Guidance Documents GUIDANCE DOCUMENT
	Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4
		 
			Draft Guidance for Industry and FDA Staff
		
		April 2013


	Download the  Draft  Guidance Document 

    Draft

	  	    Not for implementation. Contains non-binding recommendations.
	  
	  
	Share
    Post
    Linkedin

    Email
    PrintDocket Number:
		    FDA-2013-D-0362
	    	    		    Issued by:
		    Guidance Issuing Office
          Office of the Commissioner, Office of Clinical Policy and Programs, Office of Combination Products


**This guidance document is being distributed for comment purposes only.**

Contents

I. Introduction
	II. Background
	III. Discussion
	IV. What is FDA Recommending?
	V. Additional information
	FootnotesReference Information:

About this guidance document
	How to comment on this document
	To obtain copies of this document
	For questions regarding this document
	FDA offices issuing this guidance**April 2013**

I. Introduction

FDA has recognized International Organization for Standardization (ISO) Standard 11040-4 for glass syringes that are intended to deliver drugs or biological products.2 FDA has become aware of adverse events and product quality events related to connectivity problems when certain glass syringes are used with connecting devices, including connecting devices that conform to the FDA-recognized ISO 594-2 standard. "Connecting devices" include needles, needless luer connectors, adapters, and transfer units. Accordingly, FDA has determined that, for glass syringes, demonstrating conformity with the ISO 11040-4 standard alone does not ensure that the glass syringe can be properly connected to connecting devices. Therefore, this guidance identifies additional, technical information that should be submitted by sponsors who seek to rely on conformity to ISO 11040-4 for a glass syringe product.

The recommendations provided in this guidance document are applicable to the sponsor of an IDE, HDE, 510(k), or PMA for the following glass syringe products, and to the sponsor of an IND, BLA, NDA, or ANDA3 for a drug or biological product that is delivered with such a glass syringe product:

Needleless glass syringes prefilled with a drug or a biological product;
	Empty glass syringes co-packaged with a drug or a biological product and/or connecting device, and
	Empty glass syringes intended for use with marketed drugs or biological products.This document focuses mainly on connectivity issues between the glass syringe and connecting device(s). It should be used in conjunction with the following FDA guidance documents:

“*Draft Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet and Related Injectors Intended for use with Drugs and Biological Products*” (April 2009) (when finalized);
	“*Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics*” (May 1999); and
	“*Guidance on the* *Content of 510(k) Submissions for Piston Syringes,*” as appropriate.FDA guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, these guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

II. Background

Glass syringes intended to deliver drugs or biologics to a patient are a critical aspect of patient care. Typically, glass syringes are intended to connect to other devices such as needles for injection, intravenous (IV) line luer connections, needleless luer locks, adapters, and transfer units.

In November 2010 and May 2011, FDA issued Stakeholder or Safety Alerts advising of adverse events and product quality events related to connectivity problems when certain prefilled needleless glass syringes are used with some needleless IV access systems. (See FDA Drug Safety Communication: *Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone*.) These events could cause a delay in the administration of medication in emergency situations, and potentially result in serious harm to patients. The reported events occurred upon attempted connections between the needleless glass syringe and certain needles or needleless pin activated luer connectors. These events included syringe tips breaking upon injection, needles detaching during injection, and syringes breaking or jamming the IV lines or other patient use lines.

Because of these glass syringe connection events and associated adverse events, FDA has recognized that demonstrating conformity to the ISO 11040-4 standard alone does not ensure that the glass syringes can be properly connected to connecting devices. Therefore, sponsors who seek to rely on conformity to the ISO 11040-4 standard in submissions for glass syringe products should also submit information from supplemental tests to demonstrate that the glass syringe can be properly connected to connecting devices. The purpose of this guidance document is to identify the supplemental tests that should be performed, and to recommend possible design modifications, to ensure that glass syringes are properly connected to connecting devices.

III. Discussion

**A. What are the key ISO standards related to glass syringes and connecting devices and why is conformity to these standards not sufficient?**

There are two key ISO standards related to glass syringes and connecting devices, ISO 11040-4 (Prefilled Syringes - Part 4: Glass barrels for injectables and ready-to-use prefillable syringes) and ISO 594-2 (Conical fittings with 6% (Luer) taper for syringes, needles and certain other medical equipment - Part 2: Lock fittings). Both standards are currently recognized by FDA.4 FDA expects all glass syringes intended to deliver drug or biological products that meet the ISO 11040-4 standard have, as applicable, design features to connect to connecting devices.

Prior to the occurrence of the adverse events described above, the general assumption was that glass syringes that conform to the ISO 11040-4 standard would ensure connectivity (interoperability) with any connecting devices that conform to the ISO 594-2 standard. However, the glass syringe standard, ISO 11040-4, has certain undefined key dimensions. For example, the standard lacks dimensions for the glass syringe nozzle internal diameter, thickness of nozzle wall, and barrel neck curvature. In contrast, the standard for the connecting devices, ISO 594-2, has specified dimensions in these areas.5 Therefore, it is possible that a glass syringe that meets the ISO 11040-4 standard may not properly connect to a device that conforms to the ISO 594-2 standard.6 More specifically, conformance to ISO 11040-4 alone cannot ensure connectivity to connecting devices without breakage or other product performance failure as described above.

**B. What other glass syringe dimensions are critical in addition to those specified in ISO 11040-4?**

Generally, the dimensions for glass syringes that are not specified in ISO 11040-4 but that are important for the connection to connecting devices include the following:

Syringe inner and outer diameter,
	Height of the nozzle for a glass barrel syringe intended to connect to a luer lock fitting,
	Thickness of nozzle wall,
	Barrel neck curvature, and
	Dimensions to accommodate luer locks with a center pin piercing element.IV. What is FDA Recommending?

FDA recommends that sponsors submit data to demonstrate that their glass syringe has connectivity (interoperability) to connecting devices to ensure proper delivery of the drug or biological product. To achieve this, the glass syringe design and validation data should include information beyond the information needed to conform to ISO 11040-4. Recommended design or re-design options are listed in subsection A. The general types of data and information the Agency recommends in the premarket or investigational submission for glass syringes are listed in subsection B.

**A. What are the recommended design or re-design options?**

Use bonded or staked needle with appropriate sharps protection feature for subcutaneous or intramuscular injections.
	Design the glass syringe with internal dimensions that ensure connectivity to connecting devices. (Although several designs may be possible, one example might be to enlarge the internal diameter of the glass syringe nozzle to accommodate pin-piercing design of needleless connectors.)
	Develop designs for dedicated dual connections between the glass syringe and connecting devices. For example, the designs may consist of a connecting device with dual connections: one end for the glass-syringe and one end for the connecting device with which it may be used. These dedicated connections may be appropriate for co-packaging with a prefilled syringe.**B. What data and information does the Agency recommend be included in premarket submissions?**

Data and information demonstrating dimensional conformance to relevant FDA-recognized ISO standards to ensure compatibility with connecting devices:
	ISO 11040-4: applies to glass barrels of glass syringes
		ISO 594-2: applies to luer lock
		When a glass syringe is used with an injector or other device, additional ISO standards may apply. These are listed in the Section V.C of this document.
	For dimensional elements that are not addressed in the relevant ISO standards, but are otherwise critical for connectivity, the submission should include data and information demonstrating how design features address these elements. (See Section IV.A, above.) These data should include design verification and validation testing to ensure that the product can be used as intended. For example,
	If the glass syringe design is modified to add new internal diameter dimensions specifications to ensure connectivity, then design validation and functional performance data should be included in the submission.
		If changes are made to a part of a delivery system, then any submission regarding those changes should contain or reference all necessary data for the entire system. For example, a newly designed syringe tip adapter should have design validation and functional performance data to show proper interoperability with connecting devices. If the glass barrel is modified to hold the adapter, similar data should be submitted.
	Functional Performance of Syringe: The ISO standards include recommendations for the performance of glass syringes as stand-alone products, but do not include recommendations for the performance of these syringes when connected to connecting devices. Data to show syringe performance and proper connectivity in this context include, but are not limited to, the following:
	Seal Integrity Testing to assess liquid leakage, air ingress, and dye ingress once the syringe is filled with the drug or biological product as intended and when connected to a connecting device. The sensitivity of the selected test method should be specified and validated. System integrity should be demonstrated throughout the product shelf-life.
		Glide Force
		Break Force
		Separation Force
		Unscrewing Torque
		Ease of Assembly
		Resistance to Overriding
		Stress Cracking
		Validation of Graduation Markings
		Dead Space
		Coring Needle Test
		Performance testing of an anti-needlestick mechanism with a glass syringe to demonstrate safety and effectiveness as recommended in FDA’s guidance document, “*Guidance for Industry and FDA Staff: Medical Devices with Sharps Injury Prevention Features* ” (August 2005).
		Connectivity to other devices necessary for use (e.g., needles, adapters, transfer systems, extension tubing, luer connectors, and sharps prevention features).
		Injection force necessary to depress the plunger and eject the drug contents
		Tip cap removal force
		Piston seal blowback (ability of syringe with tip cap to hold a certain pressure on the piston)
	Biocompatibility: Data and information demonstrating conformance to ISO 10993 with a combination of physicochemical, analytical, and biological testing as appropriate.
	Sterilization: Data and information demonstrating consistency, as appropriate, with FDA’s guidance document, “*Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products*” (November 1994), and with FDA-recognized ISO 11135 (Ethylene oxide Sterilization) and ISO 11137 (Radiation).7 For prefilled glass syringes, additional methods may be used to demonstrate sterility assurance of the combination product, as appropriate. In cases when terminal sterilization of the combination product may not be feasible, sterility assurance should include a demonstration of syringe component sterilization and the aseptic filling with the drug/biologic and/or diluent.
	Human Factors - Data and information from human factors testing. Human factors testing and risk analysis of use errors help ensure proper design of the user interface. Sponsors must meet design control requirements in 21 CFR Part 820, including establishing and maintaining procedures to ensure that the design requirements relating to the device address the intended use of the device, including the needs of the user and patient (21 CFR 820.30(c)). Analysis of use error is particularly important when products are re-designed to mitigate connectivity and compatibility issues such as those described in this document. A hazard analysis should be submitted that, among other things, identifies any use-related risks of the product, including medication errors. For additional information, see FDA’s guidance on human factors.8.
	Performance testing for prefilled glass syringes or co-packages: Prefilled glass syringes and co-packages of drug/biological products with empty glass syringes are combination products (as described below is Section V.A). The sponsor should submit data and information from performance testing on the final assembled product filled with the drug or biologic product. Performance testing should take into consideration the viscosity of the drug or biological product, resistance created by the fluid contact path, and the back pressure/shear force generated during the injection as to whether it could alter the characteristics, functionality, safety, and/or effectiveness of the drug/biologic. In addition, testing should evaluate whether the back pressure generated during the injection could detach the needle from the syringe.
	Other testing for prefilled glass syringes and co-packages: There may be elements that impact the safety and effectiveness of prefilled glass syringes and glass syringes that are co-packaged with a drug or a biological product that are unique to the specific drug/biological product. Whether a sponsor should submit data and information to address these product-specific elements will be assessed on a case by case basis. As an example, dual-chamber prefilled glass syringes are combination products containing lyophilized drug/biologic and diluent in separate chambers of the device. For this type of syringe, the following specifics should be addressed:
	The prefilled syringe assembly which includes lyophilization of drug/biologic and subsequent aseptic filling with the diluent;
		Assurance of system integrity to exclude drug/biologic-diluent contact during storage and shipment;
		Drug/biologic reconstitution process before the syringe is connected to an administration device; and
		Comprehensive drug/biologic-device compatibility assessment.
	The submission to FDA describing each test performed should include a summary that explains the objective, acceptance criteria, sample size (statistically significant number with justification), method, results, discussion, and discussion of deviations.
	FDA notes that the above items focus specifically on the glass syringe connectivity aspects of development. For additional recommendations for product development, you should refer (as appropriate) to the following FDA guidance documents:

	*Draft Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet and Related Injectors Intended for use with Drugs and Biological Products* (April 2009);
		Guidance for Industry: *Container Closure Systems for Packaging Human Drugs and Biologics;* (May 1999); and
		*Guidance on the* *Content of 510(k) Submissions for Piston Syringes* (April 1993).V. Additional Information

**A. What is the regulatory pathway for submitting a marketing application for a prefilled glass syringe or a co-package of glass syringe with a drug or a biological product?**

Glass syringes prefilled with drug or biological products are combination products under 21 CFR Part 3. Specifically, they meet the combination product definition under 21 CFR 3.2(e)(1). A co-package of a drug or biological product and an empty glass syringe (“co-packaged glass syringe”) also meets the definition of a combination product under 21 CFR 3.2(e)(2).

Combination products are assigned to a lead center based on the primary mode of action as defined in 21 CFR 3.2(m). For a prefilled or co-packaged glass syringe with a drug or biological primary mode of action (PMOA), CDER (Center for Drug Evaluation and Research) or CBER (Center for Biologics and Research) is the lead center. Applications requesting approval to conduct clinical trials or to market these products are generally submitted under an IND, BLA, NDA, or ANDA. The device information may be included in these submissions or it may be provided in a device master file.9 There are also general use empty (unfilled) syringes for injection of unidentified drug/biological products. These are marketed under a device premarket notification, 510(k).10

Regardless of submission type, when a master file is used, the master file submitter should provide a letter to the application holder to authorize master file cross-reference. FDA does not approve the master file; FDA regulatory action is on the investigational or marketing application. FDA will, however, notify the master file holder of any deficiencies related to the master file only. As with other medical products, the overall application holder is responsible for resolution of any product specific deficiencies. To that end, for applicants with prefilled or co-packaged glass syringes, FDA recommends that the applicant work closely with their manufacturers and suppliers to address the issues described in this document.

**B. Does FDA recommend early interactions with the Agency?**

We recommend that you have early discussions with FDA if you are developing a glass syringe or injector that uses the type of glass syringe described in this document. If you are uncertain about the type of technical and scientific information that may be appropriate or necessary for your submission, FDA encourages you to request a joint meeting with the involved FDA centers (CBER/CDER and CDRH) and appropriate product representatives (the applicant, the device manufacturer if not the applicant, etc.). In these meetings we recommend that you outline your proposed steps to ensure the connectivity of the glass syringe when connected to connecting devices. For a glass syringe prefilled or otherwise intended for use with a specific drug or biological product, drug/biologic-specific information is available from the CDER or CBER review division. Additional general device information is available from the CDRH, General Hospital Devices Branch at 301-796-2585. For combination product policy, procedures, and regulatory questions you may contact the Office of Combination Products by email to combination@fda.gov. General guidance information and links to the different center documents are accessible at https://www.fda.gov/combination-products.

**C. What are the related guidance and FDA recognized standards?**

Many of the concepts described in this document are detailed further in other agency documents. The following FDA guidance and informational documents may be useful when developing a glass syringe.

*Guidance for Industry and FDA Staff - Technical Considerations for Pen, Jet and Related Injectors Intended for Use with Drugs and Biological Products,* (June 2013), available at: https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM147095.pdf
	*Guidance for Industry and FDA Staff - Medical Devices with Sharps Injury Prevention Features* (August 2005), available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/medical-devices-sharps-injury-prevention-features-guidance-industry-and-fda-staff
	*Guidance for Industry and Food and Drug Administration Staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design* (February 2016), available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices
	*Guidance for Industry - Container Closure Systems for Packaging Human Drugs and Biologics*(May 1999), available at; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics , and the associated Guidance for Industry -Container Closure Systems for Packaging Human Drugs and Biologics, Questions and Answers (May 2002), available at; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-packaging-human-drugs-and-biologics-questions-and-answers
	Related ISO standards are listed at the FDA webpage on recognition and use of consensus standards: https://www.fda.gov/regulatory-information/standards. This website includes information describing how to access to the following standards:
	ISO 594-1: Conical Fittings with 6% (Lure) Taper for Syringes, Needles and Certain Other Medical Equipment - Part 1: General Specifications
		ISO 594-2: Conical Fittings with 6% (Lure) Taper for Syringes, Needles and Certain Other Medical Equipment - Part 1: Lock Fittings
		ISO 720: 1985: Glass - Hydrolytic Resistance of Glass Grains a 121o C - Method of Test and Classification
		ISO 7864: Sterile Hypodermic Needles for Single Use
		ISO 7886-1: Sterile Hypodermic Syringes for Single Use - Part 1: Syringes for Manual Use
		ISO 7886-2: First Edition 1996-05-15: Sterile Hypodermic syringes for Syringes for Single Use - Part 2: Syringes for use with power driven syringe pumps
		ISO 7886-3: First Edition 1996-05-15: Sterile Hypodermic syringes for Syringes for Single Use - Part 3: Auto-disposable syringes for fixed-dose immunization
		ISO 10993-1: Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing
		ISO 11040-4: Prefilled Syringes Part 4: Glass Barrel for Injectables
		ISO 11135-1: 2007: Sterilization of Health Care Products - Ethylene Oxide - Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices
		ISO 11137-1: 2006(R) 2010: Sterilization of Health Care Products - Radiation - Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices
		ISO 11137-2: 2006 Sterilization of Health Care Products - Radiation - Part 2: Establishing the sterilization dose
		ISO 11137-3: 2006(R) 2010 Sterilization of Health Care Products - Radiation - Part 3: Guidance of dosimetric aspects
		ISO 11608-1: Pen-Injectors for Medical Use - Part 1: Pen-injectors - Requirements and test methods
		ISO 11608-2: Pen-Injectors for Medical Use - Part 2: Needles - Requirements and test methods
		ISO 11608-3: Pen-Injectors for Medical Use - Part 3: Finished Cartridge - Requirements and test methods
		ISO 11608-4: Pen-Injectors for Medical Use - Part 4: Requirements and test methods for electronic and electromechanical pen-injector.Footnotes

1. This guidance was prepared by the Office of Combination Products in the Office of the Commissioner in conjunction with the Center for Devices and Radiological Health, the Center for Drug Evaluation and Research, and the Center for Biologics Evaluation and Research.

2. The FDA database of currently recognized versions of these ISO documents is accessible at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfStandards/search.cfm. This website identifies the currently recognized version and any addition guidance information.

3. These submission abbreviations refer to the following: IDE is an investigational device exemption; HDE is a humanitarian device exemption; 510(k) is a premarket notification; PMA is a premarket application; IND is an investigational new drug application; BLA is a biologics license application; NDA is a new drug application; and ANDA is an abbreviated new drug application.

4. Guidance for Industry and FDA Staff: Technical Considerations for Pen, Jet and Related Injectors Intended for Use with Drugs and Biological Products (June 2013), available at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM147095.pdf

5. Guidance for Industry, Container Closure systems for Packaging Human Drugs and Biologics (May 1999), available at; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070551.pdf.

6. Guidance on the Content of 510(k) submissions for Piston Syringes (April 1993), available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm081324.htm

7. Needleless Pre-filled Glass Syringes: Stakeholder Advisory - Compatibility Problems with Needleless Intravenous Access Systems; https://www.fda.gov/drugs/drug-safety-and-availability/letter-stakeholders-update-certain-needleless-pre-filled-glass-syringes

8. FDA Drug Safety Communication: Connection problems involving certain needleless pre-filled glass syringes containing adenosine and amiodarone; http://www.fda.gov/Drugs/DrugSafety/ucm254215.htm

9. See footnote 2.

10. Plastic syringe ISO standard 7886 has internal dimensions that are compatible with the ISO 594-2 standard.

11. For example, assume a given pin-piercing needleless connector complies with ISO 594-2. FDA has received reports that when such a pin-piercing needleless connector is mated with a glass syringe, the pin could jam and break the glass syringe when threaded together.

12.Guidance for Industry and FDA Staff - Medical Devices with Sharps Injury Prevention Features (August 2005), available at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071663.htm

13. Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products (November 1994), available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072171.pdf

14. See footnote 2. For further recommendations on device sterility, you may consult FDA’s guidance document, Guidance for Industry and FDA Staff: Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile (January 2016), available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submission-and-review-sterility-information-premarket-notification-510k-submissions-devices-labeled

15. 21 CFR 820.30(c).

16. Guidance for Industry and Food and Drug Administration Staff - Applying Human Factors and Usability Engineering to Optimize Medical Device Design (February 2016), available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/applying-human-factors-and-usability-engineering-medical-devices. See also FDA’s “Human Factors and Medical Devices” webpage, available at: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/human-factors-and-medical-devices.

17. See footnote 4.

18. See footnote 5.

19. See footnote 6.

20. See FDA’s “Introduction to Master Files for Devices (MAFs),” available at: https://www.fda.gov/medical-devices/premarket-approval-pma/master-files

21. Empty glass syringes marketed in isolation for general use are under regulated under 21 CFR 880.5860. See also Guidance on the Content of Premarket Notification [510(K)] Submissions for Piston Syringes (April 1993), available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm081324.htm.

About This Guidance Document

This draft guidance, when finalized, will represent the Food and Drug Administration’s (FDA’s) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

How to comment on this document

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the*Federal Register*.

To obtain copies of this document

Additional copies are available from:

Office of Combination Products
Office of Special Medical Programs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Avenue, WO-32 Hub 5129
Silver Spring, MD 20993
(Tel) 301-796-8930
(Fax) 301-796-8619http://www.fda.gov/CombinationProducts/default.htm

For questions regarding this document

For questions regarding this document, contact the Office of Combination Products at combination@fda.gov or Patricia Y. Love, MD at 301-796-8933 or *patricia.love@fda.hhs.gov*

FDA offices that issued this guidance

**U.S.****Department of Health and Human Services******Food and Drug Administration****

Center for Devices and Radiological Health
	Center for Drug Evaluation Research
	Center for Biologics Evaluation and Research
	Office of Combination Products in the Office of the CommissionerSubmit Comments
	   		  			    		Submit Comments Online
					You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
						If unable to submit comments online, please mail written comments to:
						Dockets Management
							Food and Drug Administration
							5630 Fishers Lane, Rm 1061
							Rockville, MD 20852
						All written comments should be identified with this document's docket number: FDA-2013-D-0362.

                                                                                  Content current as of:
      02/21/2020
         
                  
Regulated Product(s)
		 Biologics
			  			     			  			     Drugs
			     			  			     Medical DevicesTopic(s)
			  Combination ProductsSearch for FDA Guidance Documents

        Search for FDA Guidance Documents

          
                        Search General and Cross-Cutting Topics Guidance Documents
          Advisory Committee Guidance Documents
          Import and Export Guidance Documents
          Cross-cutting Guidance Documents
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop